CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Search

We found 7163 result(s)

Workshop: Combining Different Types of Evidence on Effectiveness, Implementation, and Views to Better Understand Complex Interventions

Event Date: April 14, 2021
Result type: Events

Audience: Producers
Level: Intermediate What you’ll learn: Workshop participants will: 1) articulate the differences between traditional effectiveness reviews and mixed methods research syntheses (MMRS); 2) identify when an MMRS would be appropriate; 3) demonstrate an understanding of the different stages of MMRS. Dr. Quan Nha Hong, In...

Workshop – Diagnostic Test Accuracy Meta-Analysis

Event Date: March 10, 2021
Result type: Events

Audience: Of interest to HTA producers. Level: Intermediate  What you’ll learn: Knowledge of methods needed to carry out a meta-analysis of diagnostic test accuracy, including the methods needed to correct for imperfect reference standard. Dr. Nandini Dendukuri, McGill University Ian Schiller, McGill University Health Centre‒Research ...

Workshop - Supporting Decision-Making in an Uncertain Future: A Hands-On Introduction to Horizon Scanning in Health Technology Management

Event Date: March 3, 2021
Result type: Events

Audience: Of interest to HTA producers. Level: Introductory What you’ll learn: By the end of this workshop, you will understand the role horizon scanning plays in health technology management (HTM), know about sources and processes to identify and prioritize horizon scanning topics, and be able to apply processes to real-world examples. Jef...

human insulin (Entuzity KwikPen)

Last Updated: February 24, 2021
Result type: Reports
Product Line: Reimbursement Review
Generic Name: human insulin
Indications: ​To improve glycemic control in adults and children with diabetes mellitus requiring more than 200 units of insulin per day.

  • Brand Name: Entuzity KwikPen
  • Manufacturer: Eli Lilly Canada Inc.
  • Project Number: SR0672-000
  • Project Status: Active
  • Submission Type: Initial

romosozumab (Evenity )

Last Updated: February 24, 2021
Result type: Reports
Product Line: Reimbursement Review
Generic Name: romosozumab
Indications: The treatment of osteoporosis in postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture.

  • Brand Name: Evenity
  • Manufacturer: Amgen Canada Inc.
  • Project Number: SR0676-000
  • Project Status: Active
  • Submission Type: Initial

budesonide (Jorveza )

Last Updated: December 22, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: budesonide
Indications: Indicated for the induction and maintenance of clinico-pathological remission in adults with eosinophilic esophagitis (EoE).

  • Brand Name: Jorveza
  • Manufacturer: AVIR Pharma Inc
  • Project Number: SR0666-000
  • Project Status: Active
  • Submission Type: Initial

nintedanib (Ofev)

Last Updated: December 22, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: nintedanib
Indications: Treatment of other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype (also known as progressive fibrosing ILD)

  • Brand Name: Ofev
  • Manufacturer: Boehringer Ingelheim (Canada) Ltd.
  • Project Number: SR0654-000
  • Project Status: Active
  • Submission Type: Initial

osimertinib (Tagrisso )

Last Updated: February 24, 2021
Result type: Reports
Product Line: Reimbursement Review
Generic Name: osimertinib
Indications: Tagrisso (osimertinib) is indicated as adjuvant therapy after tumour resection in patients with stage IB-IIIA non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations. • A validated test is required to identify EGFR mutation-positive status (exon 19 deletions or exon 21 (L858R) substitution mutations) prior to treatment.

  • Brand Name: Tagrisso
  • Manufacturer: AstraZeneca Canada Inc.
  • Project Number: PC0246-000
  • Project Status: Pending
  • Submission Type: Initial

luspatercept (Reblozyl )

Last Updated: February 23, 2021
Result type: Reports
Product Line: Reimbursement Review
Generic Name: luspatercept
Indications: Reblozyl (luspatercept for injection) is indicated for:  the treatment of adult patients with red blood cell (RBC) transfusion-dependent anemia associated with beta(β)-thalassemia.  the treatment of adult patients with transfusion-dependent anemia requiring at least two RBC units over 8 weeks resulting from very low- to intermediate-risk myelodysplastic syndromes (MDS) who have ring sideroblasts and who have failed or are not suitable for erythropoietin-based therapy.

  • Brand Name: Reblozyl
  • Manufacturer: Celgene Inc., a Bristol Myers Squibb company
  • Project Number: SR0670-000
  • Project Status: Received
  • Submission Type: Initial